FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890923998> ?p ?o ?g. }

• W2890923998 abstract "e18118 Background: Precision oncology – use of tumor genomic profiling to guide therapies – is widely discussed but with limited real-world data. We have previously reported our prospective study on feasibility and clinical utility of routine somatic genomic testing of solid tumors [ J Natl Cancer Inst. 2015; 108(3)], and here we report our longitudinal experience, focusing on therapeutic impact. Methods: Records were reviewed for consecutive adult patients seen at Cleveland Clinic for a solid tumor malignancy without known curative options where tumor genomic profiling was ordered using FoundationOne™ (Cambridge, MA). Results were discussed at the Cleveland Clinic Genomics Tumor Board, and therapeutic recommendations were conveyed to the primary oncologist. Data for this cohort study approved by the Cleveland Clinic IRB included subsequent therapies and clinical outcomes. Results: From 2013 to 2016, 330 patients had tumor genomic testing ordered. Median age was 61 years (range, 24-94); 170 (51.5%) were female; 289 (87.6%) were Caucasian. Colorectal (21.5%), breast (17%), lung (16.1%), and pancreatobiliary (11.5%) cancers were the most common diagnoses. In 300 resulted cases, a median of 4 (0-20) alterations per specimen were noted; the most commonly altered genes were TP53 (n = 174), KRAS (n = 75), APC (n = 65), CDKN2A/B (n = 49), and PIK3CA/ PIK3R (n = 46). A specific therapy targeting an actionable alteration was recommended in 51% (153/300) of patients, and 11.7% (n = 35) received such therapy: 14 on clinical trials, 5 on-label, and 16 off-label. Most common targets for therapy were PIK3CA/PIK3R/PTEN (n = 7), HER2 (6), BRAF (3), EGFR (3), and ALK, FLT3, NTRK1 and RET (2 each). At last follow-up, of 35 patients receiving targeted therapy, best responses were: complete response (n = 1, 2.9%), partial response (n = 5, 14.3%), stable disease (n = 14, 40%), progressive disease (n = 11, 31.4%); data not available for 4 patients. Non-availability of clinical trials was a common reason for non-receipt of targeted therapy. Conclusions: Tumor genomic profiling influenced treatment in 11.7% of patients in this cohort, and 57% of those receiving targeted therapy experienced clinical benefit. These data can help guide real-world discussions of precision oncology." @default.
• W2890923998 created "2018-09-27" @default.
• W2890923998 creator A5002170706 @default.
• W2890923998 creator A5005961410 @default.
• W2890923998 creator A5026717218 @default.
• W2890923998 creator A5031507854 @default.
• W2890923998 creator A5039576853 @default.
• W2890923998 creator A5045738764 @default.
• W2890923998 creator A5057402683 @default.
• W2890923998 creator A5059260412 @default.
• W2890923998 creator A5065605420 @default.
• W2890923998 creator A5088914288 @default.
• W2890923998 date "2017-05-20" @default.
• W2890923998 modified "2023-10-12" @default.
• W2890923998 title "Precision oncology experience at a tertiary care center." @default.
• W2890923998 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18118" @default.
• W2890923998 hasPublicationYear "2017" @default.
• W2890923998 type Work @default.
• W2890923998 sameAs 2890923998 @default.
• W2890923998 citedByCount "0" @default.
• W2890923998 crossrefType "journal-article" @default.
• W2890923998 hasAuthorship W2890923998A5002170706 @default.
• W2890923998 hasAuthorship W2890923998A5005961410 @default.
• W2890923998 hasAuthorship W2890923998A5026717218 @default.
• W2890923998 hasAuthorship W2890923998A5031507854 @default.
• W2890923998 hasAuthorship W2890923998A5039576853 @default.
• W2890923998 hasAuthorship W2890923998A5045738764 @default.
• W2890923998 hasAuthorship W2890923998A5057402683 @default.
• W2890923998 hasAuthorship W2890923998A5059260412 @default.
• W2890923998 hasAuthorship W2890923998A5065605420 @default.
• W2890923998 hasAuthorship W2890923998A5088914288 @default.
• W2890923998 hasConcept C121608353 @default.
• W2890923998 hasConcept C126322002 @default.
• W2890923998 hasConcept C143998085 @default.
• W2890923998 hasConcept C185592680 @default.
• W2890923998 hasConcept C19527891 @default.
• W2890923998 hasConcept C2776598537 @default.
• W2890923998 hasConcept C2779463800 @default.
• W2890923998 hasConcept C2991842025 @default.
• W2890923998 hasConcept C2992520072 @default.
• W2890923998 hasConcept C509974204 @default.
• W2890923998 hasConcept C512399662 @default.
• W2890923998 hasConcept C71924100 @default.
• W2890923998 hasConcept C8010536 @default.
• W2890923998 hasConceptScore W2890923998C121608353 @default.
• W2890923998 hasConceptScore W2890923998C126322002 @default.
• W2890923998 hasConceptScore W2890923998C143998085 @default.
• W2890923998 hasConceptScore W2890923998C185592680 @default.
• W2890923998 hasConceptScore W2890923998C19527891 @default.
• W2890923998 hasConceptScore W2890923998C2776598537 @default.
• W2890923998 hasConceptScore W2890923998C2779463800 @default.
• W2890923998 hasConceptScore W2890923998C2991842025 @default.
• W2890923998 hasConceptScore W2890923998C2992520072 @default.
• W2890923998 hasConceptScore W2890923998C509974204 @default.
• W2890923998 hasConceptScore W2890923998C512399662 @default.
• W2890923998 hasConceptScore W2890923998C71924100 @default.
• W2890923998 hasConceptScore W2890923998C8010536 @default.
• W2890923998 hasLocation W28909239981 @default.
• W2890923998 hasOpenAccess W2890923998 @default.
• W2890923998 hasPrimaryLocation W28909239981 @default.
• W2890923998 isParatext "false" @default.
• W2890923998 isRetracted "false" @default.
• W2890923998 magId "2890923998" @default.
• W2890923998 workType "article" @default.